Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ASXBV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huAD208.4.1 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Leucine-rich repeat-containing protein 15 (LRRC15) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HuAD208.4.1-vcMMAE-DAR4 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
86.91% (Day 21)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
LRRC15 expression on stromal cells asassessed by IHC in an untreated xenograft tumor of 200-800 mm in volume, representative for eachxenograft model. In vivo activity of huAD208.4.1-vcMMAE-DAR4 (3 mg/kg) was demonstrated in EBC-1 xenografts.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
HuAD208.4.1-PBD-DAR2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
91.00% (Day 18)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
EBC-1 squamous NSCLC cells (5 million) were implanted subcutaneously into SCID mice, and mice were randomized when the tumors reached 225 mm and dosed with ADC at 0.6 mg/kg Q7Dx2 (one dose given every 7 days for a total of 2 doses) or isotype antibody at 6 mg/kg intraperitoneally starting on day 0.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
95.80% (Day 26)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
NCI-H1650 adeno NSCLCcells (5 million) were implanted subcutaneously into SCID/Beige mice, and mice were randomized whenthe tumors reached 225 mm and dosed with ADC at 0.6 mg/kg or isotype antibody at 12 mg/kg intraperitoneally once on day 0.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 nM
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
In vitro cell killing in murine Balb/c BM-MSC (Cyagen) mesenchymal stem cells in thepresence of 10 ng/mL TGF by isotype-PBD-DAR2 or huAD208.4.1-PBD-DAR2. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Normal | Mouse bone marrow-derived mesenchymal stem (BM-MSC) cells | Mus musculus | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 nM-100.00 Nm
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
In vitro cell killing in human BM-MSC (Lonza) mesenchymalstem cells in the presence of 10 ng/mL TGFB by isotype-PBD-DAR2 or huAD208.4.1-PBD-DAR2. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Normal | Human bone marrow-derived mesenchymal stem (BM-MSC) cells | Homo sapiens | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.